Showing 141 - 160 results of 22,576 for search '(((( c largest decrease ) OR ( ((a large) OR (b large)) decrease ))) OR ( 19 cases increased ))', query time: 1.81s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145

    Image_2_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  6. 146

    Image_1_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  7. 147

    Image_4_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  8. 148

    Image_3_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  9. 149

    Table1_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.docx by Chaofeng Zhang (845343)

    Published 2024
    “…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”
  10. 150

    Image1_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.JPEG by Chaofeng Zhang (845343)

    Published 2024
    “…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”
  11. 151

    Image2_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.JPEG by Chaofeng Zhang (845343)

    Published 2024
    “…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”
  12. 152

    Supplementary Material for: STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma by Xiao S. (11834801)

    Published 2021
    “…However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. …”
  13. 153

    Image_4_The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.jpeg by Zhouning Lin (14648597)

    Published 2023
    “…Background<p>Gut microbiota characteristics in patients with diffuse large B-cell lymphoma (DLBCL) are reportedly different when compared with the healthy population and it remains unclear if the gut microbiota affects host immunity and clinical disease features. …”
  14. 154

    Image_1_The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.jpeg by Zhouning Lin (14648597)

    Published 2023
    “…Background<p>Gut microbiota characteristics in patients with diffuse large B-cell lymphoma (DLBCL) are reportedly different when compared with the healthy population and it remains unclear if the gut microbiota affects host immunity and clinical disease features. …”
  15. 155

    Image_5_The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.jpeg by Zhouning Lin (14648597)

    Published 2023
    “…Background<p>Gut microbiota characteristics in patients with diffuse large B-cell lymphoma (DLBCL) are reportedly different when compared with the healthy population and it remains unclear if the gut microbiota affects host immunity and clinical disease features. …”
  16. 156

    Image_3_The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.jpeg by Zhouning Lin (14648597)

    Published 2023
    “…Background<p>Gut microbiota characteristics in patients with diffuse large B-cell lymphoma (DLBCL) are reportedly different when compared with the healthy population and it remains unclear if the gut microbiota affects host immunity and clinical disease features. …”
  17. 157

    Image_2_The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.jpeg by Zhouning Lin (14648597)

    Published 2023
    “…Background<p>Gut microbiota characteristics in patients with diffuse large B-cell lymphoma (DLBCL) are reportedly different when compared with the healthy population and it remains unclear if the gut microbiota affects host immunity and clinical disease features. …”
  18. 158
  19. 159

    Predicting Electrophoretic Mobility of Proteoforms for Large-Scale Top-Down Proteomics by Daoyang Chen (4732431)

    Published 2020
    “…We argue that predicting retention/migration time of proteoforms from the RPLC/CZE separation accurately and comparing their predicted and experimental separation time could be a useful and practical approach. Based on our knowledge, there is still no report in the literature about predicting separation time of proteoforms using large top-down proteomics data sets. …”
  20. 160